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Animal model of aluminum-induced osteomalacia: Role of chronic
renal failure. Both aluminum toxicity and a relative deficiency of
parathyroid hormone have been implicated in the development of
osteomalacia in dialysis patients. To study the effect of intraperitoneal
(IP) aluminum injections on bone histology and parathyroid hormone
and to determine if chronic renal failure accentuates aluminum toxicity,
rats were divided into five groups: normals (N); low dose aluminum
(LDA), 0.1 mg IP aluminum daily; high dose aluminum (HDA), 1.0mg
IP aluminum daily; chronic renal failure (CRF); and chronic renal
failure plus high dose aluminum (CRF-HDA). At the conclusion of the
study, there were no differences between N and LDA rats. Between the
other groups, marked differences were observed. Compared to N rats,
the relative osteoid volume (P < 0.02) and the osteoid seam width (P <
0.001) were increased in HDA, CRF, and CRF-HDA rats. Percent
resorption and osteoclasts!mm2 were increased in CRF rats (P < 0.02)
and decreased in HDA rats (P < 0.05). Compared to N rats, the amino
terminal parathyroid hormone was decreased in HDA rats (P < 0.02)
despite the presence of hypocalcemia. These data suggest that (1)
aluminum toxicity produces osteomalacia; (2) a relative parathyroid
hormone deficiency may be a contributory factor; (3) chronic renal
failure increases the severity of aluminum-induced osteomalacia; and
(4) chronic renal failure alone does not result in osteomalacia.
Un modèle animal d'ostéomalacie induite par I'aluminium: Role de
I'insuffisance rénale chronique et de l'hormone parathyroIdienne. La
toxicité de l'aluminium et un deficit relatif en hormone parathyroI-
dienne ont tous les deux été impliqués dans Ic developpement de
l'ostéomalacie chez les malades en dialyse. Afin d'étudier l'effet
d'injections intrapéritoneales (IP) d'aluminium sur l'histologie osseuse
et l'hormone parathyroldienne et de determiner si l'insuffisance rénale
chronique accentue La toxicité de l'aluminium, des rats ont été divisés
en cinq groupes: normaux (N); faible dose d'aluminium (LDA), 0,1 mg
d'aluminium IP par jour; forte dose d'aluminium (HDA), 1,0 mg
d'aluminium IP par jour; insuffisance rénale chronique (CRF); insuffi-
sance rénale chronique plus forte dose d'aluminium (CRF-HDA). A la
fin de l'étude il n'y avait pas de difference entre les rats N et LDA. Des
differences importantes ont été observées entre les autres groupes. Par
rapport aux rats N, le volume ostéoIde relatif (P < 0,02) et l'epaisseur
des bordures ostéoIdes (P < 0,001) étaient augmentés chez tes rats
HDA, CRF, et CRF-HDA. Le pourcentage de resorption et les ostéo-
clastes/mm2 étaient augmentes chez les rats CRF (P < 0,02) et diminués
chez les rats HDA (P < 0,05). Par rapport aux rats N, l'hormone
parathyroldienne aminoterminale était diminuée chez les rats HDA (P
<0,02) malgré l'existence dune hypocalcemie. Ces données suggérent
que (1) Ia toxicité aluminique entraine une ostéomalacie; (2) un deficit
relatif en hormone parathyroIdienne peut Ctre un facteur contributif; (3)
l'insuffisance rénale chronique augmente Ia sévérité de l'ostéomalacie
induite par l'aluminium; (4) l'insuffisance rénale chronique seule n'en-
traine pas d'ostéomalacie.
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Several lines of evidence implicate aluminum as a causal
factor in the production of dialysis-associated osteomalacia.
During the early 1970's, investigators in Great Britain noted the
association between the high aluminum content of the dialysate
water and osteomalacia in patients with chronic renal failure [1,
2]. In 1976, Alfrey, Le Gendre, and Kaehny documented
increased aluminum content of bone in dialysis dependent
patients [3]. Subsequent reports have confirmed elevated alumi-
num concentration in the bone of chronic renal failure patients
[4], but some discrepancy exists whether or not the total
aluminum concentration of bone is higher in dialysis dependent
individuals with osteomalacia than osteitis fibrosa [5, 6]. Inde-
pendent groups of investigators, utilizing different techniques,
have confirmed the presence of aluminum at the interface of
osteoid and mineralized bone [6, 7]. This observation suggests
that aluminum may interfere with the normal mineralization
process. In addition, Ellis, McCarthy, and Herrington demon-
strated in the rat that prolonged daily administration of intra-
peritoneal aluminum resulted in impaired mineralization at the
growth plate [4].
Recent clinical observations suggest that a relative deficiency
of parathyroid hormone may be a contributory factor in the
genesis of dialysis-associated osteomalacia. The vast majority
of affected patients have levels of parathyroid hormone that
range from undetectable to minimal elevations, and are, in
general, markedly below the levels of dialysis patients with
osteitis fibrosa [8, 9]. When the parathyroid hormone response
to hypocalcemia was studied in osteomalacic patients, a blunted
parathyroid hormone response was observed [10]. Finally, the
appearance of osteomalacia in several dialysis patients after
parathyroidectomy for osteitis fibrosa has been reported [II].
These observations suggest that a relative parathyroid hormone
deficiency may contribute to the evolution of osteomalacia.
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The present study in rats was initiated to evaluate the role of
aluminum in the development of osteomalacia and its effect on
parathyroid hormone concentrations. Because clinical reports
of osteomalacia have focused on chronic renal failure patients,
this study was designed to determine if renal failure accentuates
the toxicity of aluminum and if the presence of aluminum in
bone could be documented by histologic techniques. In addi-
tion, the mineralization process was evaluated by double tetra-
cycline labeling.
Methods
Male Wistar rats ranging in weight from 174 to 225g were
divided randomly into five groups: Normals (N); low dose
aluminum (LDA) — each rat received 0.1 mg of elemental
aluminum (5 days/week) as an intraperitoneal injection of
aqueous aluminum chloride; high dose aluminum (HDA) —
each rat received 1.0 mg of elemental aluminum (5 days/week)
as an intraperitoneal injection of aqueous aluminum chloride;
chronic renal failure (CRF) — chronic renal failure was surgi-
cally created in each rat; chronic renal failure with high dose
aluminum (CRF-HDA) — chronic renal failure was surgically
created in each rat, and each rat received 1.0 mg elemental
aluminum (5 days/week) as an intraperitoneal injection of
aqueous aluminum chloride. The LDA rats received a total dose
of 7.65 mg of elemental aluminum and the high dose aluminum
rats (HDA and CRF-HDA) a total dose of 59 mg of elemental
aluminum during the study. Normal rats received an equal
volume of diluent over the same injection schedule. Chronic
renal failure was surgically created by left papillectomy [12]
followed 1 week later by right nephrectomy.
All rats had free access to water and were fed a standard rat
chow diet (Rodent Laboratory Chow #5001, Ralston Purina
Co., St. Louis, Missouri) containing 1.2% calcium, 0.86%
phosphorus, and 5.3 IU/g vitamin D. The rats were weighed at
regular intervals. The N and LDA rats were studied simulta-
neously and sacrificed after 120 days. After sacrifice of N and
LDA rats, studies of the other three groups were initiated.
Because of the attrition rate in the HDA and CRF-HDA rats,
early sacrifice of the last three groups was performed between
90 and 100 days. In all groups prior to sacrifice, two intraperito-
neal injections of aqueous tetracycline (20 mg/kg) were given
separated by 7 or 8 days. Two CRF-HDA rats received only a
single tetracycline injection and a third CRF-HDA rat did not
receive tetracycline because of premature death.
At the time of sacrifice, blood was obtained by cardiac
puncture for serum phosphorus and urea nitrogen, and plasma
calcium and immunoreactive amino and carboxy parathyroid
hormone. Plasma calcium was measured with an automated
calcium analyzer (Calcette, model 4008, Precision System, Inc.,
Sudbury, Massachusetts). Serum phosphorus was determined
with an autoanalyzer (Technicon, Ardsley, New York). The
serum urea nitrogen was measured with a specific kit (Urea
nitrogen test set, model #580, Stanbio TM, San Antonio,
Texas). Plasma immunoreactive parathyroid hormone, both
amino and carboxy terminal fragments, was determined by
radioimmunoassay with a method previously described [13].
After exsanguination, the body of the ischium and the iliac
wing were detached from the skeleton and placed in 70%
ethanol. After dehydration and defatting, the bone was embed-
ded in methyl methacrylate. Sectioning of the block was
accomplished with a sledge microtome (Jung, Model K, Heidel-
berg, West Germany). For histomorphometric analysis, 5-j-
Goidner stained sections were examined. Teii-micron sections
were stained for aluminum by the method of Maloney et a! [7].
Fifteen-micron unstained sections were utilized for analysis of
the tetracycline labels. All analyses were begun below the
ossification zone of the iliac cartilage plate. Goidner-stained
sections of cancellous bone were analyzed at a magnification
x500 with a Merz-Schenk reticle [141. All histomorphometric
assessments were accomplished with the aid of a Leitz Ortho-
lux II microscope (Leitz, Wetzlar, West Germany).
Measurements of trabecular bone were made in the following
categories: (I) Osteoblastic osteoid, the fraction or density of
trabecular surface covered by plump osteohlasts; (2) osteoid
seams, the fraction or density of trabecular surface covered by
osteoid; (3) bone-osteoclast interface, the fraction or density of
trabecular surface covered by osteoclasts; (4) total resorption,
the fraction or density of trabecular surface covered by resorp-
tion lacunae (active and inactive); (5) relative osteoid volume,
the fraction of trabecular bone volume occupied by osteoid; (6)
bone volume, the fraction of cancellous bone volume occupied
by bone matrix; (7) osteoclast/mm2, the number of osteoclasts
per square millimeter of cancellous bone; (8) osteoid seam
width, directly measured with a micrometer: (9) bone apposi-
tional rate, the mean distance between tetracycline labels
divided by the number of days between doses of tetracycline;
(10) mineralization lag time, obtained by dividing the osteoid
seam width by the daily appositional rate; (11) percent mineral-
ization, the fraction of osteoid mineralizing as assessed by
tetracycline label; and (12) bone formation rate, the area of
mineralized bone formed within a unit area of bone per day.
This value was obtained by the formula: Bone formation rate
equals surface area per unit trabecular area times bone apposi-
tional rate (/d). As opposed to Melsen and Mosekilde [151 who
include both the double and single tetracycline labeled surface,
only the double tetracycline labeled surface was used in this
study to calculate the bone formation rate. The calculations are
uncorrected for the obliquity of the section plane.
Results are expressed as mean values SD. The significance
of the differences between groups was assessed by the unpaired
test or the Mann-Whitney U test (MW) [161.
Results
The prolonged intraperitoneal administration of high dose
aluminum in rats resulted in profound osteomalacia. Bone
histomorphometric analysis revealed significant differences be-
tween groups except N and LDA rats. Although differences
were observed between HDA and CRF-HDA rats, in general,
the administration of high dose aluminum resulted in increased
osteoid volume and surface, decreased bone formation, and
decreased bone resorption. Histologic differences between
groups of rats can be appreciated in Figure 1. Both HDA and
CRF-HDA rats are characterized by increased osteoid deposits,
while CRF rats demonstrate increased osteoblastic and osteo-
clastic activity.
Table 1 provides a comparison of the measured and calculat-
ed histomorphometric parameters and the statistical analysis.
When compared to N rats, osteoblastic osteoid was increased in
CRF rats and decreased in CRF-HDA rats. A marked difference
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Fig. 1. Goldner-stained sections of trabecular bone. A Normal rat trabecular bone. To be noted is the scarcity of osteoid seams. (x200) B
Trabecular bone of HDA rat. Apparent are several large, acellular osteoid deposits (dark area). (x200) C Trabecular bone of CRF rat. Osteoclasts
are present along the inferior margin of the trabecular bone and an osteoid seam with osteobtasts an the superior surface. (x 500) D Trabecular bone
of CRF-HDA rat. Large, irregular, and acellular deposits of osteoid are widely distributed along the bone surface. (x200)
in osteoblastic osteoid existed between CRF rats, and both high
dose aluminum groups (HDA and CRF-HDA). Total surface
osteoid was increased in both CRF and CRF-HDA rats. Bone
osteoclast interface was increased in CRF rats and reduced in
HDA and CRF-HDA rats. Osteoclasts/mm2, another indicator
of bone resorption, were increased in CRF rats and decreased
in the HDA and CRF-HDA rats. Osteoid seam width was
increased markedly in the FIDA, CRF, and CRF-HDA rats.
Comparisons among these last three groups revealed that the
osteoid seam width was broader in HDA and CRF-HDA rats
than CRF rats; and osteoid seam width in CRF-HDA rats
exceeded the value for HDA rats.
Bone volume was not different in any of the five groups.
However, marked differences were noted in osteoid volume.
The relative osteoid volume was increased in HDA, CRF, and
CRF-HDA rats. The relative osteoid volume present in CRF-
HDA rats was greater than the relative osteoid volume in HDA
and CRF rats. Thus, the data indicate that high dose aluminum,
both in rats with normal renal function and chronic renal failure,
resulted in the presence of excessive osteoid.
Except in the CRF-HDA rats, the percent of mineralizing
osteoid was uniformly 100%. The quality and intensity of the
tetracycline fluorescence was different in the two groups receiv-
ing high dose aluminum. In general, the tetracycline labels were
irregular, attenuated, and less intense than those observed in
the other groups. Differences in tetracycline labeling between
groups are shown in Figure 2. Displayed are the tetracycline
labels observed at both the ossification zone and trabecular
bone. LDA rats are not shown because no dilTerences from N
rats were noted. Marked abnormalities at the cartilage plate and
the adjacent ossification zone are seen in HDA, CRF, and CRF-
HDA rats. With respect to trabecular bone, distinct double
tetracycline labels are present in N and CRF rats. The trabecu-
lar bone of HDA and CRF-HDA rats was characterized by the
complete absence of or infrequently observed double tetracy-
cline labels.
When compared to N rats, the bone formation rate was
increased in CRF rats and decreased in HDA and CRF-HDA
rats. The bone appositional rate was decreased only in the CRF-
HDA rats when compared to N rats. However, one HDA rat
displayed no double labels. In the HDA rats with double labels,
the number of double labels was decreased although the dis-
tance between labels was not diminished. When CRF-HDA rats
were compared to CRF rats, the bone appositional rate was
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Table 1. Comparison of histologic data between groups of rats
reduced in the CRF-HDA rats. The mineralization lag time was
increased minimally in CRF rats, markedly elevated in ITIDA
rats, and infinity in CRF-HDA rats.
Biochemical findings are displayed in Table 2. The carboxy
terminal parathyroid hormone level was increased in CRF rats
compared to HDA rats. A decrease in amino terminal parathy-
roid hormone was found in HDA rats despite hypocalcemia.
The serum phosphorus concentration was increased in HDA
rats. In CRF rats, a marked variation existed in serum phospho-
rus values. The plasma calcium concentration was decreased in
HDA rats compared with the other groups. As expected, the
serum urea nitrogen was elevated in the CRF and CRF-HDA
rats.
We used a histologic staining technique for the detection of
aluminum and found deposits of aluminum only in HDA and
CRF-HDA rats. Aluminum deposits were observed at the
interface of osteoid and mineralized bone, along the neutral
bone surface, and infrequently at cement lines (Fig. 3). Their
presence appeared to correlate directly with the absence of
double tetracycline labels.
The rats receiving high dose aluminum exhibited a diminished
rate of weight gain. A dramatic example suggesting that intra-
peritoneal injections of high dose aluminum inhibit weight gain
is evident when HDA rats are compared to CRF rats (Fig. 4). At
the completion of the surgery for chronic renal failure, the CRF
rats weighed less than HDA rats (intraperitoneal aluminum not
yet begun). By the time of sacrifice, the CRF rats had gained
more weight than HDA rats. The combination of renal insuffi-
N LDA HDA CRF CRF-HDA N LDA HDA CRF CRF-HDA
Osteoblastic osteoid,
% total trabecular surface
6.58
5.27
(4)a
7.84
3.67
(5)
1.84
2.71
(5)
12.03
2.55
(6)
0.24
0.54
(5)
x NS NS
x
P < 0.1
P < 0.001
x
P < 0.05
NS
p < 0.001
Total osteoid,
% total trabecular surface
12.0
9.85
(4)
14.54
7.61
(5)
19.16
6.68
(5)
24.15
6.78
(6)
46.04
(5)
x NS NS
x
P < 0.05
NS
x
P < 0.05
P < 0.05
P < 0.1
Bone-osteoclast interface,
% total trabecular surface
10.7
4.2
(4)
8.06
2.8
(5)
3.06
1.02
(5)
15.55
6.6
(6)
3.48
2.14
(5)
x NS P < 0.01 P < 0.02 (MW)
P < 0.005
x
P < 0.02
NS
P < 0.005
Total resorption,
% total trabecular surface
11.4
2.76
(4)
9.4
3.22
(5)
3.94
1.44
(5)
19.57
11.92
(6)
4.42
2.79
(5)
x NS P <0.005
x
P <0.01 (MW)
P < 0.02
x
P < 0.01
NS
P < 0.025
Osteoclasts/mm2 3.93
1.00
(4)
4.04
1.34
(5)
1.7
1.05
(5)
8.13
2.92
(6)
2.34
1.38
(5)
x NS P < 0.02
x
P < 0.05
P < 0.005
X
P < 0.1
NS
'' < 0.005
Osteoid seam width,
micron
3.30
1.47
(4)
3.66
1.91
(5)
14.85
(5)
7.61
6.17
(6)
22.92
(5)
x NS P < 0.001
x
P < 0.001
P < 0.001
x
P < 0.001
P < 0.005
P < 0.001
Relative osteoid volume,
% trabecular bone
1.57
1.07
(4)
2.28
1.41
(5)
6.84
2.46
(5)
6.47
2.70
(6)
23.02
13.41
(5)
x NS P < 0.01
x
P < 0.01
NS
x
P < 0.02
P < 0.05
P < 0.02
Bone volume,
% cancellous bone
18.3
3.65
(4)
20.16
3.29
(5)
17.78
7.0
(5)
21.53
4.08
(6)
19.74
5.86
< NS NS
x
NS
NS
x
NS
NS
NS
Bone appositional rate,
micron/day
1.66
0.16
(4)
1.72
0.33
(5)
1.59
0.89
(5)
2.22
0.58
(6)
0
0
(2)
x NS NS
x
NS
NS
x
P < 0.001
P < 0.1
P < 0.005
Bone formation rate,
mm2/mm2/d x JO
5.88
2.36
(4)
6.05
2.72
(5)
0.82
0.77
(5)
19.32
12.79
(6)
0
0
(2)
x NS P < 0.005
x
P < 0.01 (MW)
P < 0.02
x
P < 0.05
NS
P < 0.05 (MW)
Mineralization lag time,
days
2.00
0.32
(4)
2.16
0.63
(5)
7.8
2.16
(4)
3.23
1.08
(6) (2)
x NS P < 0.005
x
P < 0.1
P < 0.05
Abbreviations: N, normal rats; LDA, low dose aluminum—each rat received 0.1 mg of elemental aluminum (5 days/week i.p.); HDA, high dose
aluminum—each rat received 1.0mg of elemental aluminum (5 days/week i.p.); CRF, chronic renal failure—chronic renal failure was surgically
created in each rat; CRF-HDA, chronic renal failure with high dose aluminum—chronic renal failure was surgically created in each rat and each rat
received 1.0 mg elemental aluminum (5 days/week i.p.); NS, not significant; MW, Mann-Whitney U test.
a The number in parentheses is the number of rats.
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ciency and high dose aluminum (CRF-HDA rats) further accen-
tuated the failure to increase weight.
Discussion
This study confirms that prolonged aluminum administration
can produce osteomalacia in an animal model and chronic renal
failure accentuates the severity of osteomalacia, Evidence for
the pathogenic role of aluminum is suggested by histologic
documentation of aluminum both at the interface of osteoid and
mineralized bone and along the neutral bone surface. Further-
more, the double tetracycline label technique demonstrates that
aluminum administration results in reduced bone formation,
and a marked prolongation of the mineralization lag time. In
addition to alterations of bone formation, high dose aluminum
also resulted in a reduction of bone resorption which cannot be
explained entirely by differences in levels of baseline carboxy
and amino terminal parathyroid hormone.
The present data validate a potential role for aluminum in the
development of osteomalacia. Hypophosphatemia was not
present in any of the groups and thus did not contribute to the
development of osteomalacia [171. Possible reasons for alumi-
num toxicity resulting in more severe osteomalacia in the
presence of renal failure include: (1) the failure to excrete the
aluminum burden because of renal insufficiency [181, and (2)
bone turnover is more rapid with renal failure and any impair-
ment of bone formation will result in a greater accumulation of
osteoid if mineralization decreases before osteoid deposition.
Despite the presence of aluminum on the bone surface and at
the interface of osteoid and mineralized bone, the mechanism
by which aluminum impairs the mineralization process is un-
known. Aluminum has been postulated to interfere with phos-
phate metabolism in bone tissue [4, 191. The mineralization
defect may not be irreversible since renal failure patients
afflicted with osteomalacia may have a significant improvement
in bone mineralization after treatment with a combination of
24,25 and 1,25 dihydroxycholecalciferol [201.
Alteration of vitamin D metabolism is a known cause of
osteomalacia [21, 22], and the possibility exists that aluminum
toxicity produces osteomalacia by affecting vitamin D metabo-
lism. However, in dialysis patients with osteomalacia, levels of
25 hydroxycholecalciferol are normal [8, 11]. As is true with all
dialysis patients, 1,25 dihydroxycholecalciferol levels are ex-
pected to be undetectable or very low [23]. Thus, since dialysis
patients with osteitis fibrosa also have low levels of 1,25
dihydroxycholecalciferol, this vitamin D metabolite would not
appear to be the sole responsible agent. Patients with normal
renal function, receiving intravenous parenteral hyperalimenta-
tion contaminated with aluminum, have been reported to devel-
op osteomalacia and to have low concentrations of 1,25 dihy-
droxycholecalciferol [24, 25]. However, a specific role for
aluminum is unclear since other investigators have reported low
1,25 dihydroxycholecalciferol levels in patients receiving intra-
venous parenteral nutrition not contaminated with aluminum
[261. Thus, although it is an attractive hypothesis to link
aluminum-induced osteomalacia with altered vitamin D metab-
olism, firm evidence in support of such a hypothesis is lacking.
Bone mineralization and formation were assessed by use of a
double tetracycline label [15, 271. Although the percent mineral-
ization did not adequately separate groups, the quality and
intensity of the tetracycline label were different in HDA and
CRF-HDA rats. A more discriminating parameter is bone
formation rate; in both groups of rats receiving high dose
aluminum, almost complete cessation of bone formation was
evident. The minimal increase in mineralization lag time ob-
served in CRF rats was secondary to increased matrix synthesis
and not as in HDA and CRF-HDA rats to decreased bone
formation. In both HDA and CRF-HDA rats, aluminum depos-
its were documented histologically at the interface of osteoid
and mineralized bone. A major question not addressed in this
study is the reversibility of the aluminum-induced osteomala-
cia. Ellis, McCarthy, and Herrington in their study provided
evidence that discontinuation of aluminum injections resulted in
resumption of mineralization at growth plate but not the trabec-
ular bone [4]. The study by Coburn et al, in which a combina-
tion of 24,25 and 1,25 dihydroxycholecalciferol was adminis-
tered to dialysis dependent patients with osteomalacia, suggests
that the mineralization block may be superceded without appar-
ent alteration of environmental exposure [20]. Another poten-
tially applicable therapy is the use of the chelating agent,
desferrioxamine, to remove aluminum 128, 29].
The CRF rats displayed increased bone formation when
compared to the other groups. Since the baseline amino and
carboxy terminal parathyroid hormone levels were not different
between the CRF and N groups, we cannot specifically ascribe
the increase in bone formation to parathyroid hormone. Other
than an increase in serum urea nitrogen, no biochemical param-
eter adequately separated the two groups.
When compared to the adult human, the magnitude of bone
resorption is much greater in the growing rat [9, 30]. Neverthe-
less, the number of osteoclasts/mm2 in our normal rats is not
very different from values reported by Shires et al [31]. The
CRF rats exhibited a significant increase in the number of
osteoclasts/mm2. Even chronic renal failure did not substantial-
ly increase the number of osteoclasts/rnm2 in the CRF-HDA
rats. One possible explanation for decreased osteoclasts/mm2 in
the HDA rats is the decreased amino terminal parathyroid
hormone concentration. However, such an explanation is not
applicable to the CRF-HDA rats. Thus, the possibility exists
that aluminum has a direct toxic effect on osteoclastic activity,
or the decrease in osteoclasts is a response to the depressed
osteoblastic activity [32].
As previously stated, circumstantial evidence suggests that a
relative parathyroid deficiency may exist in dialysis patients
with osteomalacia [8, 10, 11]. In this study, the concentrations
of parathyroid hormone were not different than N rats except
for a decreased amino terminal paratliyroid hormone in the
HDA rats which was observed despite the presence of hypocal-
cemia. The normal carboxy terminal parathyroid hormone
values for our rats are approximately twice the normal value
observed in adult humans [13]. A similar increment was seen in
a study involving young rats by Shires et al [31]. From our data
no definite conclusion can be drawn with respect to the
question of a relative parathyroid hormone deficiency. Of
interest is the decreased amino terminal fragment in HDA rats
despite a low serum calcium. The remainder of the biochemical
data provide some differences, but are not helpful in establish-
ing potential mechanisms.
Ellis, McCarthy, and Herrington noted that rats receiving
intraperitoneal aluminum failed to gain weight as rapidly as
control rats [4]. The growth failure was evident prior to the
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Fig. 2. Double tetracycline labeling of trabecular bone and ossification zone below the cartilage plate. A Cartilage plate and ossification zone of N
rat. A narrow organized band of mineralization is observed. (x200) B Trabecular bone of N rat. Several distinct double tetracycline labels,
indicating active bone formation, are seen. (x200) C Cartilage plate and ossification zone of HDA rat. The ossification zone is abnormally broad
and no double labels are present in the adjacent trabecular bone. (X200) D Trabecular bone of HDA rat. Although tetracycline labels are present
along the trabecular bone surface, no double labels are observed. (x200) E Cartilage plate and ossification zone of CRF rat. The ossification zone
is abnormally wide and disorganized. (x200) F Trabecular bone of CRF rat. Multiple double labels, indicating active bone formation, are apparent.
(x 200) G Cartilage plate and ossjication zone of CRF-HDA rat. No tetracycline deposition is seen in the ossification zone even though the rat was
given two tetracycline injections. (x200) H Trabecular bone of CRF-HDA rat. Although tetracycline labels are present on the trabecular bone
surface, no double labels were visualized. (X200)
Table 2. A comparison of biochemical data between groups of ratsa
N LDA HDA CRF CRF-HDA N LDA HDA CRF CRF-HDA
Plasma parathyroid hormone
Carboxy terminal, nglml
1.03
0.04
(3)b
0.88
0.18
(5)
1.10
0.09
(6)
1.02
0.05
(4)
x NS
x
NS
P < .05
x
NS
NS
NS
Amino terminal, ng/ml 0.30
0.14
(3)
0.07
0.04
(5)
0.23
0.12
(6)
0.23
0.12
(4)
x P < 0.02
x
NS
P<0.02
x
NS
P<0.05
NS
Plasma calcium, mgldl 9.51
0.66
(3)
9.41
0.51
(5)
8.22
0.30
(5)
9.5
0.46
(4)
8.86
1.2
(4)
x NS P < 0.01
<
NS
P < 0.005
x
NS
NS
NS
Serum phosphorus, mgldl 5.15
0.29
(4)
5.69
1.12
(5)
6.02
0.46
(5)
5.95
1.33
(6)
5.01
0.64
(4)
x NS P < 0.02
x
NS
NS
x
NS
P < 0.05
NS
Serum urea nitrogen, mg/dl 29.4
5.51
(4)
28.8
6.45
(5)
23.8
4.73
(5)
43
5.84
(6)
43.3 x
3.82
(4)
NS NS
x
P < 0.02
P < 0.001
x
P < 0.01
P < 0.001
NS
Abbreviations are the same as those in Table 1.
The number in parentheses is the number of rats.
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histologic presence of osteomalacia. Although we cannot pre-
cisely state when osteomalacia developed in our rats, a failure
to appropriately gain weight was apparent during the first
month of aluminum administration in both the HDA and CRF-
HDA rats. The precise role of aluminum in such a phenomenon
is uncertain. The possibility that aluminum produces a peritoni-
tis cannot be excluded. A specific aluminum toxicity, consisting
of periorbital bleeding, lethargy, and anorexia, described by
Berlyne et a! was not observed in our rats [33]. Aluminum
deposition in vital organs may play a role in the growth failure.
Alfrey, Hegg, and Craswell [5] have shown that tissue alumi-
num levels are elevated markedly in uremic patients. In patients
with dialysis-associated encephalopathy, bone, spleen, and
liver aluminum levels are increased markedly when compared
to other dialysis patients [5]. Thus, the injected aluminum
burden in our rats is probably widely distributed and may be
capable of producing diverse effects.
The study was designed originally to continue for at least 120
days. The N and the LDA rats were matched and treated for the
scheduled time span before sacrifice. The second matched
group included the HDA, CRF, and CRF-HDA rats. The
necessity to prematurely sacrifice these animals became evi-
dent because of the high attrition rate in both groups of rats
receiving high dose aluminum. Because of the debilitated
condition of the CRF-HDA rats, it became necessary to sacri-
fice several rats after only a single label of tetracycline. Thus, in
Fig. 3. Stain for aluminum a dark, dense line at the interface of osteoid
and bone and along some of the neutral bone surfiice.
the second matched group, sacrifice occurred between 90 and
100 days.
It would appear that an aluminum toxic rat model as devel-
oped by Ellis, McCarthy, and Herrington [4] and further
modified in the current study, may be helpful in the investiga-
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Fig. 4. Mean weight gain of three paired groups of rats, CRF (•), HDA
(0), and CRF-HDA (0). Between day 0 to day 16, the CRF and CRF-
HDA rats underwent a papillectomy and contralateral nephrectomy. By
day 16 when intraperitoneal aluminum (AL) was first injected in HDA
and CRF-HDA rats, the HDA rats had gained more weight than the
other two groups. When compared to CRF rats, the CRF-HDA rats had
decreased weight gain on days 51, 61, and 77. By day 77, the CRF rats
had gained more weight than the HDA rats despite the fact that HDA
rats had gained significantly more weight by day 16. Symbols: *, P <
0.05; **, P <0.01.
tion of dialysis-associated osteomalacia. Aluminum intoxica-
tion may produce an analogous bone disease in humans. Future
studies should evaluate the use of vitamin D metabolites which
have been reported to modify liver aluminum deposition 341,
and parathyroid hormone both in the prevention and treatment
of the osteomalacia associated with this experimental model. It
may also be possible to study the mechanism by which alumi-
num impairs bone formation.
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